Tumor necrosis factor-α-induced apoptosis is associated with suppression of insulin-like growth factor binding protein-5 secretion in differentiating murine skeletal myoblasts

Journal of Cellular Physiology

Volumn 183, Issue 3, 2000, Pages 330-337

  Meadows, Kate A ^a   Holly, Jeff M P ^a   Stewart, Claire E H ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; FIBROBLAST GROWTH FACTOR; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 5; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; MOUSE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE; CREATINE KINASE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INSULIN-LIKE GROWTH FACTOR II; MICE; MUSCLE, SKELETAL; RECOMBINANT PROTEINS; SECOND MESSENGER SYSTEMS; SPHINGOSINE; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034097181     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(200006)183:3<330::AID-JCP5>3.0.CO;2-N     Document Type: Article

References (34)

1. Cerami AC, Ikeda Y, Latrang N, Hotez PGA, Beutler B. 1985. Weight loss with an endotoxin induced mediator for peritoneal macrophages: the role of cachectin (tumour necrosis factor). Immunol Lett 11:173-177.
2. Cheng J, Turksen K, Yu QC, Schreiber H, Teng M, Fuchs E. 1992. Cachexia and grafts-vs.-host-disease-type skin changes in keratin promoter-driven TNFalpha transgenic mice. Genes Dev 6:1444-1456.
3. Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, Santoni A, Testi R. 1993. Apoptotic signalling through CD95 (Fas/ Apo-1) activates an acid sphingomyelinase. J Exp Med 177:1547-1552.
4. Davis SC, Wass JH, Ross RJM, Cotterill AM, Buchanan CR, Coulson VJ, Holly JMP. 1991. The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. J Endocrinol 130:469-473.
5. Dbaibo GS, Obeid LM, Hannun YA. 1993. Tumour necrosis factor-α (TNFα) signal transduction through ceramide. J Biol Chem 268: 17762-17766.
6. Ellaurie M, Rubinstein A. 1992. Tumour necrosis factor alpha in paediatric HIV-1 infection. AIDS 6:1265-1268
7. Ewton DZ, Roof SL, Magri KA, McWade FJ, Florini JR. 1994. IGF-II is more active than IGF-I in stimulating L6A1 myogenesis: greater mitogenic actions of IGF-I delay differentiation. J Cell Physiol 161: 277-284.
8. Florini JR, Ewton DZ, Falen SL, Van Wyk JJ. 1986. Biphasic concentration dependency of stimulation of myoblast differentiation by somatomedins. Am J Physiol 250:C771-778.
9. Florini JR, Magri KA, Ewton DZ, James PL, Grindstaff K, Rotwein PS. 1991. "Spontaneous" differentiation of skeletal myoblast is dependant upon autocrine secretion of insulin-like growth factor-II. J Biol Chem 266:15917-15923.
10. Florini JR, Ewton DZ, McWade FJ. 1995. IGFs, muscle growth and myogenesis. Diabetes Rev 3:73-92.
11. Green BN, Jones SB, Streck RD, Wood TL, Rotwein P, Pintar JE. 1994. Distinct expression patterns of insulin-like growth factor binding proteins 2 and 5 during foetal and post-embryonic development. Endocrinology 134:954-962.
12. Grunfeld C, Wilking H, Neese R, Gavin LA, Moser AH, Gilli R, Serio MK, Feingold KR. 1989. Persistence of the hypertriglyceridemic effect of tumour necrosis factor despite development of tachyphylaxis to its anorectic/cachectic effects in rats. Cancer Res 49:2554-2560.
13. Gu W, Schneider JW, Condorelli G, Kaushai S, Mahdavi V, Nadal-Ginard B. 1993. Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell 72:309-324.
14. James PL, Jones SB, Busby Jr WH, Clemmons DR, Rotwein P. 1993. A highly conserved insulin-like growth factor binding protein (IGFBP-5) is expressed during myoblast differentiation. J Biol Chem 268:22305-22312.
15. James PL, Stewart CEH, Rotwein P. 1996. Insulin-like growth factor binding protein-5 modulates muscle differentiation through an insulin-like growth factor-dependant mechanism. J Cell Biol 133: 683-693.
16. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. 1991. Transgenic mice expressing tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025-4031.
17. Kolesnick R, Golde DW. 1994. The sphingomyelin pathway in tumour necrosis factor and interleukin-1 signalling. Cell 77:325-328.
18. Oliff A. 1988. The role of tumour necrosis factor (cachectin) in cachexia. Cell 54:141-142.
19. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G. Wolfe A, Socher SH. 1987. Tumours secreting human TNF/cachectin induce cachexia in mice. Cell 50:555-563.
20. Rosen KM, Wentworth BM, Rosenthal N, Villa-Komaroff L. 1993. Specific, temporally regulated expression of the insulin-like growth factor II gene during muscle cell differentiation. Endocrinology 133:474-481.
21. Rosenthal SM, Brunetti A, Brown EJ, Mamula PW, Goldfine ID. 1991. Regulation of insulin-like growth factor (IGF) I receptor expression during muscle cell differentiation: potential autocrine role of IGF-II. J Clin Invest 87:1212-1219.
22. Rosenthal SM, Cheng Z-Q. 1995. Opposing early and late effects of insulin-like growth factor-I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts. Proc Natl Acad Sci USA 92:10307-10311.
23. Saghizaden M, Ong JM, Garvey WT, Henry RR, Kern PA. 1996. The expression of TNFα by human muscle. Relationship to insulin resistance. J Clin Invest 94:1111-1116.
24. Stewart CEH, James PL, Fant ME, Rotwein P. 1996. Overexpression of insulin-like growth factor-II induces accelerated myoblast differentiation. J Cell Physiol 169:23-32.
25. Stewart CEH, Rotwein P. 1996. Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts. J Biol Chem 271:11330-11338.
26. Tepper CG, Jayadev S, Liu B, Bielawska A, Wolff R, Yonerhara S, Hannun YA, Seldin MF. 1995. Role of ceramide as endogenous mediator of Fas-induced cytotoxicity. Proc Natl Acad Sci USA 92: 8443-8447.
27. Tamura S, Ouchi KF, Mori K, Endo M, Matsumoto T, Eda H, Tanaka itsuka H, Tokita H, Yamagughi K. 1995. Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin Cancer Res 1:1353-1358.
28. Teng MN, Park BH, Keoppen HKW, Tracey KJ, Fendly BM. Schreiber HP. 1991. Long term inhibition of tumour growth by tumour necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci USA 88:3535-3539.
29. Thomas LN, Cohen P, Douglas RC, Lazier C, Rittmaster RS. 1998. Insulin-like growth factor binding protein-5 is associated with involution of the ventral prostate in the castrated and finasteride-treated rats. Prostate 35:273-278.
30. Tollefsen SE, Sadow JL, Rotwein P. 1989. Co-ordinate expression of insulin-like growth factor-II and its receptor during muscle differentiation. Proc Natl Acad Sci USA 86:1543-1547.
31. Toomey D, Redmond HP, Bouchier-Hayes D. 1995. Mechanisms mediating cancer cachexia. Cancer 76:2418-2426.
32. Tonner E, Barber MC, Travers MT, Logan A, Flint DJ. 1997. Hormonal control of insulin-like growth factor-binding protein-5 production in the involuting mammary gland of the rat. Endocrinology 138:5101-5107.
33. Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL, Rebrikov D, Brodianski VM, Kemper OC, Kollet O, Lapidot T, Soffer D, Sobe T, Avraham KB, Goncharov T, Holymann H, Lonai P, Wallach D. 1998. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apol, and DR3 and is lethal prenatally. Immunity 9:267-276.
34. Wojnar MM, Hawkins WG, Lang CH. 1995. Nutritional support of the septic patient. Crit Care Clin 11:717-733.